Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis ...Middle East

SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical...

Hence then, the article about bridge biotherapeutics announces completion of enrollment in the phase 2a clinical study of bbt 877 for the treatment of idiopathic pulmonary fibrosis was published today ( Tuesday 30/07/2024 - 01:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis )

Also on site :

• UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
• Scott Ritter say he was ‘de-banked’
• AI boom fuels fears of an industry bubble (VIDEO)